Browsing by Author "Darcan Ş."
Now showing 1 - 7 of 7
Results Per Page
Sort Options
Item The role of platelet-activating factor in pathogenesis of type 1 diabetes [1](American Diabetes Association Inc., 2005) Ersoy B.; Hüseyinov A.; Darcan Ş.[No abstract available]Item The frequency and associated factors of diabetic ketoacidosis at diagnosis in children with type 1 diabetes; [Tip 1 diyabetli çocuklarda tanıda diyabetik ketoasidoz sıklıǧı ve i̇liflkili faktörler](Galenos Yayincilik,, 2010) Demir K.; Büyükinan M.; Dizdarer C.; Şimşek D.G.; Özen S.; Asar G.; Can Ş.; Altincik A.; Özhan B.; Ersoy B.; Böber E.; Darcan Ş.Introduction: In this study, it was aimed to assess the frequency and associated factors of diabetic ketoacidosis (DKA) at diagnosis in patients with newly diagnosed type 1 diabetes who were admitted to pediatric endocrinology clinics in tertiary referral hospitals in Izmir and Manisa provinces. Materials and Method: The files of the patients were evaluated retrospectively. Data regarding sex, date of birth, family history for diabetes, and health insurances of the patients were recorded and compared with respect to the form of clinical presentation. Results: It was noted that 139 patients (M/F:74/65, mean age 8.7±3.9 years) were diagnosed in 2008. At the time of diagnosis, the clinical picture of the majority of the patients were ketosis (n=58, 41.7%) or DKA (n=57, 41%). Mortality or severe morbidity developed in none of the patients. It was detected that lack of family history for type 1 diabetes and being less than 5 years of age were associated with DKA at the time of diagnosis. When logistic regression analysis was used to perform risk analysis, only being less than 5 years of age was found to be a risk factor for DKA (p=0.008, Odds Ratio 3.3, 95% confidential interval 1.4-8.1). Conclusion: These results led us consider that large-scale campaigns/studies are needed to be performed to reduce the ratio of DKA at the time of diagnosis by making the society conscious of diabetes in childhood. © The Journal of Current Pediatrics, published by Galenos Publishing.Item Current practice in diagnosis and treatment of growth hormone deficiency in childhood: A survey from Turkey(Galenos Yayincilik,, 2015) Poyrazoğlu Ş.; Akçay T.; Arslanoğlu I.; Atabek M.E.; Atay Z.; Berberoğlu M.; Bereket A.; Bideci A.; Bircan I.; Böber E.; Can Ş.; Cesur Y.; Darcan Ş.; Demir K.; Dündar B.; Ersoy B.; Esen I.; Güven A.; Kara C.; Keskin M.; Kurtoğlu S.; Memioğlu N.; Özbek M.N.; Özgen T.; Sari E.; Şiklar Z.; Şimşek E.; Turan S.; Yeşilkaya E.; Yuksel B.; Darendeliler F.Objective: Approaches to diagnosis and treatment of growth hormone deficiency (GHD) in children vary among countries and even among centers in the same country. This survey, aiming to facilitate the process of preparing the new consensus on GHD by the Turkish Pediatric Endocrinology and Diabetes Society, was designed to evaluate the current practices in diagnosis and treatment of GHD in different centers in Turkey. Methods: A questionnaire covering relevant items for diagnosis and treatment of GHD was sent out to all pediatric endocrinology centers. Results: Twenty-four centers returned the questionnaire. The most frequently used GH stimulation test was L-dopa, followed by clonidine. Eighteen centers used a GH cut-off value of 10 ng/mL for the diagnosis of GHD; this value was 7 ng/mL in 4 centers and 5 ng/mL in 2 centers. The most frequently used assay was immunochemiluminescence for determination of GH, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 concentrations. Sex steroid priming in both sexes was used by 19 centers. The most frequently used starting dose of recombinant human GH (rhGH) in prepubertal children was 0.025-0.030 mg/kg/day and 0.030-0.035 mg/kg/day in pubertal children. Growth velocity was used in the evaluation for growth response to rhGH therapy in all centers. Anthropometric measurements of patients every 3-6 months, fasting blood glucose, bone age and thyroid panel evaluation were used by all centers at follow-up. Main indications for cessation of therapy were decreased height velocity and advanced bone age. Fourteen centers used combined treatment (rhGH and gonadotropin-releasing analogues) to increase final height. Conclusion: Although conformity was found among centers in Turkey in current practice, it is very important to update guideline statements and to modify, if needed, the approach to GHD over time in accordance with new evidence-based clinical studies. © Journal of Clinical Research in Pediatric Endocrinology.Item Turner syndrome and associated problems in turkish children: A multicenter study(Galenos Yayincilik,, 2015) Yeşilkaya E.; Bereket A.; Darendeliler F.; Baş F.; Poyrazoğlu Ş.; Aydın B.K.; Darcan Ş.; Dündar B.; Büyükinan M.; Kara C.; Sarı E.; Adal E.; Akıncı A.; Atabek M.E.; Demirel F.; Çelik N.; Özkan B.; Özhan B.; Orbak Z.; Ersoy B.; Doğan M.; Ataş A.; Turan S.; Gökşen D.; Tarım Ö.; Yüksel B.; Ercan O.; Hatun Ş.; Şimşek E.; Ökten A.; Abacı A.; Döneray H.; Özbek M.N.; Keskin M.; Önal H.; Akyürek N.; Bulan K.; Tepe D.; Emeksiz H.C.; Demir K.; Kızılay D.; Topaloğlu A.K.; Eren E.; Özen S.; Abalı S.; Akın L.; Eklioğlu B.S.; Kaba S.; Anık A.; Baş S.; Ünüvar T.; Sağlam H.; Bolu S.; Özgen T.; Doğan D.; Çakır E.D.; Şen Y.; Andıran N.; Çizmecioğlu F.; Evliyaoğlu O.; Karagüzel G.; Pirgon Ö.; Çatlı G.; Can H.D.; Gürbüz F.; Binay Ç.; Baş V.N.; Fidancı K.; Polat A.; Gül D.; Açıkel C.; Demirbilek H.; Cinaz P.; Bondy C.Objective: Turner syndrome (TS) is a chromosomal disorder caused by complete or partial X chromosome monosomy that manifests various clinical features depending on the karyotype and on the genetic background of affected girls. This study aimed to systematically investigate the key clinical features of TS in relationship to karyotype in a large pediatric Turkish patient population. Methods: Our retrospective study included 842 karyotype-proven TS patients aged 0-18 years who were evaluated in 35 different centers in Turkey in the years 2013-2014. Results: The most common karyotype was 45,X (50.7%), followed by 45,X/46,XX (10.8%), 46,X,i(Xq) (10.1%) and 45,X/46,X,i(Xq) (9.5%). Mean age at diagnosis was 10.2±4.4 years. The most common presenting complaints were short stature and delayed puberty. Among patients diagnosed before age one year, the ratio of karyotype 45,X was significantly higher than that of other karyotype groups. Cardiac defects (bicuspid aortic valve, coarctation of the aorta and aortic stenosi) were the most common congenital anomalies, occurring in 25% of the TS cases. This was followed by urinary system anomalies (horseshoe kidney, double collector duct system and renal rotation) detected in 16.3%. Hashimoto’s thyroiditis was found in 11.1% of patients, gastrointestinal abnormalities in 8.9%, ear nose and throat problems in 22.6%, dermatologic problems in 21.8% and osteoporosis in 15.3%. Learning difficulties and/or psychosocial problems were encountered in 39.1%. Insulin resistance and impaired fasting glucose were detected in 3.4% and 2.2%, respectively. Dyslipidemia prevalence was 11.4%. Conclusion: This comprehensive study systematically evaluated the largest group of karyotype-proven TS girls to date. The karyotype distribution, congenital anomaly and comorbidity profile closely parallel that from other countries and support the need for close medical surveillance of these complex patients throughout their lifespan. © Journal of Clinical Research in Pediatric Endocrinology.Item Growth curves for Turkish girls with turner syndrome: Results of the Turkish turner syndrome study group(Galenos Yayincilik,, 2015) Darendeliler F.; Yeşilkaya E.; Bereket A.; Baş F.; Bundak R.; Sarı E.; Aydın B.K.; Darcan Ş.; Dündar B.; Büyükinan M.; Kara C.; Mazıcıoğlu M.M.; Adal E.; Akıncı A.; Atabek M.E.; Demirel F.; Çelik N.; Özkan B.; Özhan B.; Orbak Z.; Ersoy B.; Doğan M.; Ataş A.; Turan S.; Gökşen D.; Tarım Ö.; Yüksel B.; Ercan O.; Hatun Ş.; Şimşek E.; Ökten A.; Abacı A.; Döneray H.; Özbek M.N.; Keskin M.; Önal H.; Akyürek N.; Bulan K.; Tepe D.; Emeksiz H.C.; Demir K.; Kızılay D.; Topaloğlu A.K.; Eren E.; Özen S.; Demirbilek H.; Abalı S.; Akın L.; Eklioğlu B.S.; Kaba S.; Anık A.; Baş S.; Ünüvar T.; Sağlam H.; Bolu S.; Özgen T.; Doğan D.; Çakır E.D.; Şen Y.; Andıran N.; Çizmecioğlu F.; Evliyaoğlu O.; Karagüzel G.; Pirgon Ö.; Çatlı G.; Can H.D.; Gürbüz F.; Binay Ç.; Baş V.N.; Sağlam C.; Gül D.; Polat A.; Açıke C.; Cinaz P.Objective: Children with Turner syndrome (TS) have a specific growth pattern that is quite different from that of healthy children. Many countries have population-specific growth charts for TS. Considering national and ethnic differences, we undertook this multicenter collaborative study to construct growth charts and reference values for height, weight and body mass index (BMI) from 3 years of age to adulthood for spontaneous growth of Turkish girls with TS. Methods: Cross-sectional height and weight data of 842 patients with TS, younger than 18 years of age and before starting any therapy, were evaluated. Results: The data were processed to calculate the 3rd, 10th, 25th, 50th, 75th, 90th and 97th percentile values for defined ages and to construct growth curves for height-for-age, weight-for-age and BMI-for-age of girls with TS. The growth pattern of TS girls in this series resembled the growth pattern of TS girls in other reports, but there were differences in height between our series and the others. Conclusion: This study provides disease-specific growth charts for Turkish girls with TS. These disease-specific national growth charts will serve to improve the evaluation of growth and its management with growth-promoting therapeutic agents in TS patients. © Journal of Clinical Research in Pediatric Endocrinology, Published by Galenos Publishing.Item Analysis of the GCK gene in 79 MODY type 2 patients: A multicenter Turkish study, mutation profile and description of twenty novel mutations(Elsevier B.V., 2018) Aykut A.; Karaca E.; Onay H.; Gökşen D.; Çetinkalp Ş.; Eren E.; Ersoy B.; Çakır E.P.; Büyükinan M.; Kara C.; Anık A.; Kırel B.; Özen S.; Atik T.; Darcan Ş.; Özkınay F.Maturity onset diabetes is a genetic form of diabetes mellitus characterized by an early age at onset and several etiologic genes for this form of diabetes have been identified in many patients. Maturity onset diabetes type 2 [MODY2 (#125851)] caused by mutations in the glucokinase gene (GCK). Although its prevalence is not clear, it is estimated that 1%–2% of patients with diabetes have the monogenic form. The aim of this study was to evaluate the molecular spectrum of GCK gene mutations in 177 Turkish MODY type 2 patients. Mutations in the GCK gene were identified in 79 out of 177. All mutant alleles were identified, including 45 different GCK mutations, 20 of which were novel. © 2017Item The effect of diabetes camp on glycemic variability in children and adolescents with type 1 diabetes mellitus(Galenos Publishing House, 2021) Ata A.; Arı G.; Işıklar H.; Demir G.; Altınok Y.A.; Ersoy B.; Özen S.; Darcan Ş.; Gökşen D.Aim: Glycemic variability can be affected in diabetes camps as a result of sports, social activities and nutrition. Close glucose monitoring is necessary to reduce glycemic variability, especially hypoglycemia. The aim assessment of glycemic variability and time in range by use of the flash glucose monitoring system (FGMS) in children and adolescents with type 1 diabetes. Materials and Methods: Thirty-three children and adolescents between 10-18 years of age who participated in the 2018 diabetes camp of Ege University were included. Their glycemic variability indexes were recorded. Results: The mean age and duration of diabetes mellitus in the study group was 13.3±0.5 and 4.9±0.7 years respectively. Twelve (43%) of the participants were boys and 16 (57%) were girls. Ten (35.7%) of the participants used continuous subcutaneous insulin infusion (CSII) pump therapy while 18 (64.3%) used multiple dose insulin therapy. When the participants were evaluated according to time in range (TIR), the duration of TIR increased, and level 1 and level 2 hyperglycemia decreased during the camp. Participants using CSII had spent more time in level 2 hypoglycemia before camp, but during and after the camp, similar values were reached for both groups. Before the camp, participants with good metabolic control had a longer duration of hypoglycemia than those participants with poor metabolic control. During and after the camp, level 1 and level 2 hypoglycemia periods were similar between the two groups. Conclusion: In diabetes camp, healthy diet, regular exercise, and close glycemic control improve glycemic variability. By using FGMS, normoglycemia periods can be increased without increasing hypoglycemic attacks. As a result, using FGMS had a positive effect on diabetes management and the control of hypoglycemia periods during the diabetes camp. © Copyright 2021 by Ege University Faculty of Medicine, Department of Pediatrics and Ege Children’s Foundation The Journal of Pediatric Research, published by Galenos Publishing House.